Norgine Completes Acquisition of Theravia

Astorg Acquires Majority Stake in Avania

June 20, 2022

Healthcare Services

Astorg has acquired a majority stake in Avania from Kester Capital, with Kester expected to retain a minority position and management also reinvesting. Avania, a Bilthoven-headquartered MedTech-focused clinical CRO, will use Astorg's capital and network to accelerate organic growth and pursue M&A to build a scaled, global MedTech CRO platform.

Boehringer Ingelheim Acquires Nerio Therapeutics

August 6, 2024

Biotechnology

Boehringer Ingelheim agreed to acquire Nerio Therapeutics, a San Diego-based preclinical biotech focused on PTPN2/N1 phosphatase inhibitors for immuno-oncology, for up to $1.3 billion. Nerio was invested/incubated by Viva BioInnovator and backed by a syndicate including Avalon Ventures; the deal is intended to accelerate development of Nerio’s preclinical program as a cornerstone of Boehringer’s immuno-oncology portfolio.

Cycle Pharmaceuticals Completes Acquisition of Applied Therapeutics

February 3, 2026

Biotechnology

Cycle Group Holdings Limited, through AT2B, Inc., completed the acquisition of NASDAQ-listed Applied Therapeutics, Inc. Applied is a clinical-stage biopharmaceutical company developing govorestat, an aldose reductase inhibitor for CNS rare metabolic diseases.

Novartis Acquires Vedere Bio

September 30, 2020

Biotechnology

Novartis has acquired Vedere Bio, a Cambridge-based optogenetics AAV gene therapy company, for $150 million upfront plus up to $130 million in potential regulatory and clinical milestones (total consideration of $280 million). The deal includes Vedere Bio's lead preclinical intravitreal AAV programs focused on pan-genotypic vision restoration; earlier-stage assets were spun out into a newly formed independent company, Vedere Bio II.

Sorrento Therapeutics Acquires ACEA Therapeutics

June 1, 2021

Biotechnology

Sorrento Therapeutics completed the acquisition of ACEA Therapeutics, making ACEA a wholly owned subsidiary and issuing Sorrento common stock plus contingent milestone and royalty payments. The deal adds multiple clinical- and preclinical-stage new chemical entities (including abivertinib) to Sorrento's oncology and immunotherapy pipeline and expands its development and manufacturing footprint in China and North America.

The Vistria Group Acquires BioCare, Inc.

November 8, 2021

Healthcare Services

The Vistria Group has acquired BioCare, Inc., a Tempe-based specialty pharmaceutical distributor, specialty pharmacy and pharmaceutical logistics provider. The deal is Vistria’s first investment from its $2.68 billion Fund IV and aims to support BioCare’s growth — both organically and via acquisitions — to expand access to therapies for rare and orphan diseases.